These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 23081753

  • 1. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
    Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM, SPRINT-2 Trial Investigators.
    Hepatology; 2013 Mar; 57(3):974-84. PubMed ID: 23081753
    [Abstract] [Full Text] [Related]

  • 2. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
    Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS, Protocol 6086 Investigators.
    Gastroenterology; 2013 Nov; 145(5):1035-1044.e5. PubMed ID: 23924660
    [Abstract] [Full Text] [Related]

  • 3. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP, Markova AA, Calle Serrano B, Cornberg M.
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
    Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH.
    J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
    [Abstract] [Full Text] [Related]

  • 5. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W, P05411 study investigators.
    Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
    [Abstract] [Full Text] [Related]

  • 6. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
    Manns MP, McCone J, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM.
    Liver Int; 2014 May; 34(5):707-19. PubMed ID: 24118703
    [Abstract] [Full Text] [Related]

  • 7. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
    Vispo E, Labarga P, Guardiola JM, Barreiro P, Miralles C, Rubio R, Miralles P, Aguirrebengoa K, Portu J, Morello J, Rodriguez-Novoa S, Soriano V, PERICO Study Group.
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):419-24. PubMed ID: 20377423
    [Abstract] [Full Text] [Related]

  • 8. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
    Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP.
    J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
    [Abstract] [Full Text] [Related]

  • 9. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
    Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F.
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
    [Abstract] [Full Text] [Related]

  • 10. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
    Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH.
    BMC Infect Dis; 2013 Apr 27; 13():190. PubMed ID: 23621902
    [Abstract] [Full Text] [Related]

  • 11. Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.
    Mandorfer M, Steiner S, Schwabl P, Payer BA, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M.
    Wien Klin Wochenschr; 2016 Jun 27; 128(11-12):414-20. PubMed ID: 26659706
    [Abstract] [Full Text] [Related]

  • 12. Boceprevir for untreated chronic HCV genotype 1 infection.
    Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators.
    N Engl J Med; 2011 Mar 31; 364(13):1195-206. PubMed ID: 21449783
    [Abstract] [Full Text] [Related]

  • 13. Boceprevir for previously treated chronic HCV genotype 1 infection.
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators.
    N Engl J Med; 2011 Mar 31; 364(13):1207-17. PubMed ID: 21449784
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P.
    Hepatol Int; 2017 Mar 31; 11(2):188-198. PubMed ID: 28210927
    [Abstract] [Full Text] [Related]

  • 15. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group.
    J Hepatol; 2013 Sep 31; 59(3):434-41. PubMed ID: 23669289
    [Abstract] [Full Text] [Related]

  • 16. Anemia management in patients with chronic viral hepatitis C.
    Hynicka LM, Heil EL.
    Ann Pharmacother; 2013 Feb 31; 47(2):228-36. PubMed ID: 23386076
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
    Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM.
    J Acquir Immune Defic Syndr; 2011 Nov 01; 58(3):261-8. PubMed ID: 21876446
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.
    Am J Kidney Dis; 2013 Oct 01; 62(4):789-95. PubMed ID: 23746377
    [Abstract] [Full Text] [Related]

  • 20. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP.
    Hepatology; 2012 Aug 01; 56(2):567-75. PubMed ID: 22619063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.